A de Leon-Casasola Ó

Language: English
References: 58
Page: 321-327
PDF size: 143.81 Kb.

Text Extraction

Introduction

The analgesic ladder was introduced under the auspices of the World Health Organization (WHO) in 1990 with the idea of providing health care providers around the world with a tool to help them implement pain therapy in patients with cancer related pain. With the suggestion that opioids could also be used for the treatment of non-cancer related pain, the principles of the analgesic ladder were eventually implemented in patients with non-cancer pain.

REFERENCES

1. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. Journal of Pain & Symptom Management 1990;5:27-32.

2. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 1986;25:171-186.

3. Ballantyne JD, Mao J. Opioid therapy for chronic pain. N Eng J Med 2003;349:1943-1953.

4. Nguyen JK, Fouts MM, Kotabe SE, Lo E. The American Journal of Geriatric Pharmacotherapy 2006;4:36-41.

5. Johnson JA, Bootman JL. Archives of Internal Medicine 1995;155:1949-1956.

6. Zarowitz BJ, Stebelsky LA, Muma BK, Romain TM, Peterson EL. Pharmacotherapy 2005;25:1636-45.

7. de Leon-Casasola OA. Multimodal approaches to the treatment of neuropathic pain: The role of topical analgesia. J Pain Symp Manag 2007;33:356-364.

8. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305.

9. Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-251.

10. Acevedo JC, Amaya A, de León Casasola OA, et al. Guías para el diagnóstico y el manejo del dolor neuropático: Consenso de un grupo de expertos latinoamericanos. Rev. Iberoamericana del Dolor 2008;3:15-46.

11. North R, Shipley J. Practice parameters for the use of spinal cord stimulation in the treatment of chronic neuropathic pain. Pain Medicine 2007;S4:S200-S275.

12. Turner JA, Sears JM, Loesser JD. Programmable intrathecal opioid delivery systems for chronic non-cancer pain: A systematic review of effectiveness and complications. Clin J Pain 2007;23:180-195.

13. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 1998;317:526-530.

14. Bratter DC. Effects of nonsteroidals anti-inflammatory drugs on renal function: focus on cyclooxigenase-2 selective inhibition. American Journal of Medicine 1999;107:65S-70S.

15. Silverstein FE, Faich F, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study-a randomized controlled trial. JAMA 2000;284:1247-55.

16. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.

17. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an under recognized public health problem. Arch Int Med 2000;160:777-84.

18. Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilization of non-steroidal anti-inflammatory drugs and hospitalized heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001;57:71-5.

19. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase 2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-6.

20. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001;345:1809-1817.

21. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004;364:665-674.

22. Anonymus. Diclofenac gel – Topical NSAIDs science. Drug and Therapeutics Bulletin 1991;29:95-96.

23. Bruhlmann P, Michael BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clinical & Experimental Rheumatology 2003;21:193-198.

24. Caldwell JR. Avinza-24 h sustained release oral morphine therapy. Expert Opinion on Pharmacotherapy 2004;5:469-472.

25. Matsumoto AK. Oral extended-release oxymorphone: A new choice for chronic pain relief. Expert Opinion on Pharmacotherapy 2007;8:151-157.

26. de Leon-Casasola OA. Implementing therapy with opioids in patients with cancer. Oncology Nursing Forum 2008;35(6):S1-6.

27. Caraceni A, Martini C, Zecca E. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliative Medicine 2004;18:177-183.

28. Payne R. Recognition and diagnosis of breakthrough pain. Pain Medicine 2007;8:S3 S7.

29. Pasternak GW. Insights into mu opioid pharmacology. The role of mu opioid receptor subtypes. Life Sciences 2001;68:2213-2219.

30. Pasternak GW. The pharmacology of mu analgesics: From patients to genes. Neuroscientist 2001;7:220-231.

31. McNicol E, Horowicz–Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. The Journal of Pain 2003;4:231-256.

32. Mercandante S, Bruera E. Opioid switching: A systematic and critical review. Cancer Treatment Reviews 2006;32:304-315.

33. Mercandante S. Opioid rotation for cancer pain. Cancer 1999;86:1856-1866.

34. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-805.

35. Harris JD, de Leon-Casasola OA. Oral erythromycin and the risk of sudden death. N. Eng J Med 2005;352:301-304.

36. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. Journal of Pharmacology and Experimental Therapeutics 1975;192:211-217.

37. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain 2002;3:377-384.

38. Zacny J, Bigelow G, Compton P, et al. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69(3):215-232.

39. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508.

40. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 Suppl):S76-82.

41. Butler SF, Budman SH, Fernandez K, et al. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004;112(1-2):65-75.

42. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-442.

43. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7:671-681.

44. Adams LL, Gatchel RJ, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 2004;27:440-459.

45. Holmes CP, Gatchel RJ, Adams LL, et al. An opioid screening instrument: long-term evaluation of the utility of the pain medication questionnaire. Pain Pract 2006;6:74-88.

46. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.

47. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995;34:667-670.

48. Rogers JF, Nafziger AN, Bertino JS, Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002;113:746-750.

49. Rheem A, Totah P, Sheffels TR, et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363–74.

50. Kadiev E, Patel V, Rad P, et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 2008;4:77-91.

51. Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003;105(1-2):231-238.

52. Supernaw RB. CYP2D6 and the efficacy of codeine and codeine-like drugs. American Journal of Pain Management 2001;11:30-31.

53. Suzuki R, Porreca F, Dickenson AH. Evidence for spinal dorsal horn hyperexcitability in rats following sustained morphine exposure. Neurosci Lett 2006;407:156-161.

54. Mercadante S, Ferrera P, Villari P, et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003;26:769-775.

55. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213-217.

56. Hong D, Byers MR, Oswald RJ. Dexamethasone treatment reduces sensory neuropeptides and nerve sprouting reactions in injured teeth. Pain 1993;55:171-181.

57. Marek P, Ben-Eliyahu S, Vaccarino AL, et al. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res 1991;558:163-165.

58. Stockler M, Vardy J, Pillai A, et al. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-3394.